Avid Bioservices (CDMO) Misses Q2 EPS by 9c, adjusts guidance

Avid Bioservices (NASDAQ: CDMO) reported Q2 EPS of ($0.15), $0.09 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $25.4 million versus the consensus estimate of $33.22 million.

GUIDANCE:

Avid Bioservices sees FY2024 revenue of $137-147 million, versus the consensus of $154.1 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight
• Carnival shares drop despite earnings beat on weak guidance